vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -9.4%). Over the past eight quarters, Smith Douglas Homes Corp.'s revenue compounded faster (17.3% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ESPR vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $260.4M |
| Net Profit | — | $3.5M |
| Gross Margin | — | 19.9% |
| Operating Margin | 50.6% | 6.5% |
| Net Margin | — | 1.4% |
| Revenue YoY | 143.7% | -9.4% |
| Net Profit YoY | — | -14.3% |
| EPS (diluted) | $0.32 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $260.4M | ||
| Q3 25 | $87.3M | $262.0M | ||
| Q2 25 | $82.4M | $223.9M | ||
| Q1 25 | $65.0M | $224.7M | ||
| Q4 24 | $69.1M | $287.5M | ||
| Q3 24 | $51.6M | $277.8M | ||
| Q2 24 | $73.8M | $220.9M | ||
| Q1 24 | $137.7M | $189.2M |
| Q4 25 | — | $3.5M | ||
| Q3 25 | $-31.3M | $2.1M | ||
| Q2 25 | $-12.7M | $2.4M | ||
| Q1 25 | $-40.5M | $2.7M | ||
| Q4 24 | — | $4.1M | ||
| Q3 24 | $-29.5M | $5.3M | ||
| Q2 24 | $-61.9M | $3.6M | ||
| Q1 24 | $61.0M | $3.0M |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 23.2% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 26.7% | ||
| Q1 24 | — | 26.1% |
| Q4 25 | 50.6% | 6.5% | ||
| Q3 25 | -11.4% | 6.6% | ||
| Q2 25 | 8.6% | 7.7% | ||
| Q1 25 | -34.0% | 8.7% | ||
| Q4 24 | -6.4% | 10.4% | ||
| Q3 24 | -31.0% | 14.2% | ||
| Q2 24 | 3.5% | 11.7% | ||
| Q1 24 | 52.5% | 11.3% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | -35.9% | 0.8% | ||
| Q2 25 | -15.4% | 1.1% | ||
| Q1 25 | -62.2% | 1.2% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | -57.2% | 1.9% | ||
| Q2 24 | -83.9% | 1.7% | ||
| Q1 24 | 44.3% | 1.6% |
| Q4 25 | $0.32 | $0.39 | ||
| Q3 25 | $-0.16 | $0.24 | ||
| Q2 25 | $-0.06 | $0.26 | ||
| Q1 25 | $-0.21 | $0.30 | ||
| Q4 24 | $-0.14 | $0.50 | ||
| Q3 24 | $-0.15 | $0.58 | ||
| Q2 24 | $-0.33 | $0.40 | ||
| Q1 24 | $0.34 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $12.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $86.7M |
| Total Assets | $465.9M | $557.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $12.7M | ||
| Q3 25 | $92.4M | $14.8M | ||
| Q2 25 | $86.1M | $16.8M | ||
| Q1 25 | $114.6M | $12.7M | ||
| Q4 24 | $144.8M | $22.4M | ||
| Q3 24 | $144.7M | $23.7M | ||
| Q2 24 | $189.3M | $17.3M | ||
| Q1 24 | $226.6M | $32.8M |
| Q4 25 | $-302.0M | $86.7M | ||
| Q3 25 | $-451.4M | $82.2M | ||
| Q2 25 | $-433.5M | $80.0M | ||
| Q1 25 | $-426.2M | $76.9M | ||
| Q4 24 | $-388.7M | $73.6M | ||
| Q3 24 | $-370.2M | $68.4M | ||
| Q2 24 | $-344.2M | $62.1M | ||
| Q1 24 | $-294.3M | $59.7M |
| Q4 25 | $465.9M | $557.6M | ||
| Q3 25 | $364.0M | $571.6M | ||
| Q2 25 | $347.1M | $570.2M | ||
| Q1 25 | $324.0M | $513.9M | ||
| Q4 24 | $343.8M | $475.9M | ||
| Q3 24 | $314.1M | $460.1M | ||
| Q2 24 | $352.3M | $429.3M | ||
| Q1 24 | $373.1M | $401.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $9.8M |
| Free Cash FlowOCF − Capex | — | $8.7M |
| FCF MarginFCF / Revenue | — | 3.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $9.8M | ||
| Q3 25 | $-4.3M | $22.8M | ||
| Q2 25 | $-31.4M | $-28.9M | ||
| Q1 25 | $-22.6M | $-34.9M | ||
| Q4 24 | $-35.0M | $5.5M | ||
| Q3 24 | $-35.3M | $22.9M | ||
| Q2 24 | $-7.2M | $39.0K | ||
| Q1 24 | $53.8M | $-9.3M |
| Q4 25 | — | $8.7M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | — | $-31.1M | ||
| Q1 25 | — | $-35.9M | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | $-35.5M | $22.3M | ||
| Q2 24 | $-7.3M | $-2.1M | ||
| Q1 24 | $53.8M | $-9.7M |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 8.2% | ||
| Q2 25 | — | -13.9% | ||
| Q1 25 | — | -16.0% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | -68.7% | 8.0% | ||
| Q2 24 | -9.9% | -1.0% | ||
| Q1 24 | 39.0% | -5.1% |
| Q4 25 | 0.0% | 0.4% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.2% | ||
| Q2 24 | 0.1% | 1.0% | ||
| Q1 24 | 0.1% | 0.2% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | 10.70× | ||
| Q2 25 | — | -12.24× | ||
| Q1 25 | — | -13.01× | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | 4.28× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | 0.88× | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
